Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21340355 | 1.00 | USP30 (0.39) | USP30MAPK1P2RX7NR1H2USP2 | |
| SCHEMBL12461395 | 1.00 | USP30 (0.39) | USP30MAPK1P2RX7NR1H2USP2 | |
| SCHEMBL19078451 | 0.88 | USP30 (0.38) | USP30MAPK1P2RX7NR1H2USP2 | |
| SCHEMBL17157711 | 0.86 | USP30 (0.38) | USP30MAPK1P2RX7NR1H2USP2 | |
| SCHEMBL31267019 | 0.85 | USP30 (0.38) | USP30MAPK1P2RX7NR1H2ATM | |
| SCHEMBL17667432 | 0.83 | MAPK1 (0.40) | MAPK1P2RX7 | |
| SCHEMBL27240613 | 0.83 | MAPK1 (0.40) | MAPK1P2RX7 | |
| SCHEMBL27240308 | 0.82 | MAPK1 (0.39) | MAPK1P2RX7SMN1; SMN2 | |
| SCHEMBL27240314 | 0.82 | MAPK1 (0.39) | MAPK1P2RX7SMN1; SMN2 | |
| SCHEMBL20182988 | 0.80 | USP30 (0.38) | USP30MAPK1P2RX7USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024165050-A1 | PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD | AUBRAK THERAPEUTICS (CN) | 2024-08-15 | — | — | WO | disclosed |
| EP-4157844-B1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-07-10 | — | — | EP | disclosed |
| EP-4329744-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-5-(1-PIPERIDIN-4-YL)ISOINDOLINE-1,3-DIONE DERIVATIVES AND USES THEREOF | Neomorph, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117355299-A | Substituted 2- (2, 6-dioxopiperidin-3-yl) -5- (1-piperidin-4-yl) isoindoline-1, 3-dione derivatives and uses thereof | 尼奥莫夫公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116940578-A | 5- [5- (piperidin-4-yl) thieno [3,2-C ] pyrazol-2-yl ] indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases | 雷密克斯医疗公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| WO-2023133229-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-4161519-A1 | PURINES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022232536-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-5-(1-PIPERIDIN-4-YL)ISOINDOLINE-1,3-DIONE DERIVATIVES AND USES THEREOF | NEOMORPH, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022184849-A1 | GLP-1R AGONISTS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | LES LABORATOIRES SERVIER (FR) | 2022-09-09 | — | — | WO | disclosed |
| US-20220220104-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2022-07-14 | — | — | US | disclosed |
| WO-2020200316-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2020-10-08 | — | — | WO | disclosed |
| WO-2018137619-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3006438-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014192868-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | USP30 3702/4885MAPK1 645/4885P2RX7 770/4885 |
| US-20220220104-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | RET, BRAF, RAF1 | USP30 4281/4885MAPK1 150/4885P2RX7 860/4885 |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | LIMK1, LIMK2, ROCK1 | USP30 4553/4885MAPK1 42/4885P2RX7 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.